Esr1 Mutated Metastatic Breast Cancer Epidemiology Forecast Insight

DelveInsight’s ‘ESR1 Mutated Metastatic Breast Cancer - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

ESR1 Mutated Metastatic Breast Cancer Disease Understanding

Metastatic breast cancer is essentially a Stage IV breast cancer wherein cancer originates in breast tissue and then spreads to other body parts. The steroid hormone, estradiol, plays a vital role in breast cancer progression, and a majority of human breast cancers start as estrogen-dependent and express the estrogen receptor (ER). ERα is the major ER subtype in the mammary epithelium and plays a critical role in mammary gland biology and breast cancer progression.


Estrogen receptor alpha (ERα), encoded by the ESR1 gene, is a member of the nuclear hormone receptor superfamily that is expressed in ∼70% of newly diagnosed breast cancers. Most of the breast cancers are ERα positive and are, therefore, treated with endocrine therapies. ESR1 mutations are acquired most frequently when aromatase inhibitors are used to treat advanced breast cancer are more frequently selected in cancers that progress after sensitivity to prior aromatase inhibitor therapy and are relatively rare in patients with intrinsic endocrine resistance.


ESR1 Mutated Metastatic Breast Cancer Diagnosis

At the time of diagnosis, tumor tissue and baseline liquid biopsies could be used for mutation detection using sensitive next-generation sequencing or MPS. Following neoadjuvant therapy, ddPCR could be employed to confirm ESR1 mutations. ddPCR could also be used to monitor mutation status during hormone therapy via blood sampling during standard follow-up visits. These liquid biopsies could also be used to monitor emerging driver mutations and subclonal evolution during therapy which would affect hormone therapy sequencing and enable precision therapy on an individual basis. Plasma sample (ctDNA) and ddPCR technology are new and reliable for the determination of ESR1 mutation.

Continued in the report…..

ESR1 Mutated Metastatic Breast Cancer Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of HR-positive breast cancer, stage-specific diagnosed prevalent cases of HR-positive breast cancer, total diagnosed prevalent cases of metastatic breast cancer, and diagnosed prevalent cases of ESR1 mutated metastatic breast cancer scenario of ESR1 Mutated Metastatic Breast Cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

ESR1 Mutated Metastatic Breast Cancer Detailed Epidemiology Segmentation

  • According to DelveInsight, in 2020, it is estimated that the total diagnosed prevalent cases of HR-positive breast cancer in the 7MM were 1,158,467. It was noted that among diagnosed prevalent cases of HR-positive breast cancer in the 7MM, the maximum number of cases were occupied by the United States (494,584), in 2020.
  • Based on the different stages of the disease, diagnosed prevalent population of HR+ breast cancer varied as 464,909 and 29,675 for early-stage and distant/metastatic stage breast cancer cases, respectively in the United States for the year 2020.
  • In the 7MM, the diagnosed prevalent cases of metastatic breast cancer were 341,748 in 2020. That also includes early-stage cases which progressed to metastatic stage.
  • In 2020, the diagnosed prevalent cases of metastatic breast cancer in the US were 145,902, these cases also included early-stage cases which progressed to metastatic. The diagnosed prevalent metastatic breast cancer cases are likely to increase by 2030 at a CAGR of 2.17%.
  • In the United States, the diagnosed prevalent cases of ESR1 mutated metastatic breast cancer was 24,575 in 2020 which included 17,654 cases from first-line and 6,920 cases from the second line.
  • Among EU-5 countries, Germany captured the highest diagnosed prevalent cases of ESR1 mutated metastatic breast cancer with 6,585 cases, followed by France (5,534 cases) and Italy (5,278 cases) in 2020. Spain consistently showed to possess the least cases among other EU5 countries throughout the study period (2018–2030).
  • In Japan, the diagnosed prevalent cases of ESR1 mutated metastatic breast cancer was 7,426 in 2020 which included 5,335 cases from first-line and 2,091 cases from the second line of treatment.

Scope of the Report

  • The report covers the descriptive overview of ESR1 Mutated Metastatic Breast Cancer, explaining various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of ESR1 Mutated Metastatic Breast Cancer.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM total diagnosed prevalent cases of HR-positive breast cancer, stage-specific diagnosed prevalent cases of HR-positive breast cancer, total diagnosed prevalent cases of metastatic breast cancer, and diagnosed prevalent cases of ESR1 mutated metastatic breast cancer.

Report Highlights

  • 10-Year Forecast of ESR1 Mutated Metastatic Breast Cancer
  • 7MM Coverage
  • Total diagnosed prevalent cases of HR-positive breast cancer
  • Stage-specific diagnosed prevalent cases of HR-positive breast cancer
  • Total diagnosed prevalent cases of metastatic breast cancer
  • Diagnosed prevalent cases of ESR1 mutated metastatic breast cancer

Key Questions Answered

  • What are the disease risk and burdens of ESR1 Mutated Metastatic Breast Cancer?
  • What is the historical ESR1 Mutated Metastatic Breast Cancer patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of ESR1 Mutated Metastatic Breast Cancer at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ESR1 Mutated Metastatic Breast Cancer?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of ESR1 Mutated Metastatic Breast Cancer during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The ESR1 Mutated Metastatic Breast Cancer report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM ESR1 Mutated Metastatic Breast Cancer epidemiology forecast.
  • The ESR1 Mutated Metastatic Breast Cancer epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The ESR1 Mutated Metastatic Breast Cancer epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. ESR1 Mutated Metastatic Breast Cancer Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of ESR1 Mutated metastatic breast cancer in 2018

3.2. Patient Share (%) Distribution of ESR1 Mutated metastatic breast cancer in 2030

4. Executive Summary of ESR1 Mutated Metastatic Breast Cancer

5. Disease Background and Overview

5.1. Introduction

5.2. ESR1 Mutations

5.2.1. The Spectrum of ESR1 Alterations is found in Metastatic ER+ Breast Cancer

5.2.2. Subgroups at Increased Risk of Developing ESR1 Mutations

5.3. Endocrine therapy

5.3.1. Mechanisms of Endocrine Therapy Resistance

5.4. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Epidemiology Assumptions and Rationale

6.4. Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the 7MM

6.5. Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the 7MM

6.5.1. Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the First Line in the 7MM

6.5.2. Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the Second Line plus in the 7MM

6.6. United States

6.6.1. Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the United States

6.6.2. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States

6.6.3. Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the United States

6.7. EU-5

6.7.1. Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the EU-5

6.7.2. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the EU-5

6.7.3. Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the EU-5

6.8. Japan

6.8.1. Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in Japan

6.8.2. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan

6.8.3. Diagnosed Prevalent Cases of ESR1 Mutation Metastatic Breast Cancer in Japan

7. KOL Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of ESR1 Mutated Metastatic Breast Cancer Epidemiology (2018–2030)

Table 2: Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the 7MM, in Thousand (2018–2030)

Table 3: Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the 7MM, in Thousand (2018–2030)

Table 4: Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the First Line in the 7MM, in Thousand (2018–2030)

Table 5: Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the Second Line Plus in the 7MM, in Thousand (2018–2030)

Table 6: Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the United States, in Thousand (2018–2030)

Table 7: Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States, in Thousand (2018–2030)

Table 8: Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the United States, in Thousand (2018–2030)

Table 9: Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the EU-5, in Thousand (2018–2030)

Table 10: Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)

Table 11: Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)

Table 12: Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in Japan, in Thousand (2018–2030)

Table 13: Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan, in Thousand (2018–2030)

Table 14: Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in Japan, in Thousand (2018–2030)

List of Figures

Figure 1: Location of ESR1 Missense Mutations Found in Clinical Samples

Figure 2: The Spectrum of ESR1 Alterations is found in Metastatic ER+ Breast Cancer

Figure 3: Schematic Representation of Identification of ESR1 Mutations in Metastatic Breast Cancer

Figure 4: Diagrammatic Representation of Known Mechanisms of Resistance to Endocrine Therapy

Figure 5: Endocrine Resistance Mechanisms and Altered ER Functions In Breast Cancer and Novel Therapeutic Strategies

Figure 6: Diagnosis of ESR1 Mutation

Figure 7: Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the 7MM, in Thousand (2018–2030)

Figure 8: Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the 7MM, in Thousand (2018–2030)

Figure 9: Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the First Line in the 7MM, in Thousand (2018–2030)

Figure 10: Total Diagnosed Prevalent Population of ESR1 Mutated Metastatic Breast Cancer in the Second Line plus in the 7MM, in Thousand (2018–2030)

Figure 11: Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the United States, in Thousand (2018–2030)

Figure 12: Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States, in Thousand (2018–2030)

Figure 13: Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the US, in Thousand (2018–2030)

Figure 14: Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in the EU-5, in Thousand (2018–2030)

Figure 15: Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)

Figure 16: Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in the EU-5, in Thousand (2018–2030)

Figure 17: Stage-specific Diagnosed Prevalent Cases of HR+ Breast Cancer in Japan, in Thousand (2018–2030)

Figure 18: Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan, in Thousand (2018–2030)

Figure 19: Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer in Japan, in Thousand (2018–2030)

Forward to Friend

Need A Quote